Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381784 | 0.93 | ADORA1 (0.71) | ADORA1SLC6A3 | |
| SCHEMBL382526 | 0.93 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL8028162 | 0.93 | ADORA1 (0.73) | ADORA1SLC6A3 | |
| SCHEMBL12910823 | 0.92 | ADORA1 (0.63) | ADORA1SLC6A3 | |
| SCHEMBL8028210 | 0.91 | ADORA1 (0.59) | ADORA1SLC6A3 | |
| SCHEMBL10195768 | 0.91 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| SCHEMBL3728434 | 0.90 | ADORA1 (0.75) | ADORA1SLC6A3 | |
| SCHEMBL3727883 | 0.90 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL3739334 | 0.89 | ADORA1 (0.79) | ADORA1SLC6A3 | |
| SCHEMBL3730903 | 0.89 | ADORA1 (0.73) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609686-B2 | Substituted azabicyclic compounds and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| EP-2235011-B1 | SUBSTITUTED PYRROLO[2, 3-B]AND PYRAZOLO[3, 4-B]PYRIDINES FOR USE AS ADENOSINE RECEPTOR LIGANDS | Bayer Pharma AG (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2235011-B1 | SUBSTITUTED PYRROLO[2, 3-B]AND PYRAZOLO[3, 4-B]PYRIDINES FOR USE AS ADENOSINE RECEPTOR LIGANDS | Bayer Pharma AG (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2009080197-A1 | SUBSTITUTED PYRROLO[2, 3-B] AND PYRAZOLO[3, 4-B] PYRIDINES FOR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | ADORA1 2110/4885SLC6A3 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.